cancers-logo

Journal Browser

Journal Browser

Molecular Markers and Targets in Modern Gynecologic Oncology

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 31 December 2026 | Viewed by 129

Editors


E-Mail Website
Guest Editor
Gynaecologic Oncology Unit, 2nd Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki, Greece
Interests: gynecologic oncology; advance laparoscopic surgery; robotic surgery; clinical research
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Gynaecologic Oncology Unit, 2nd Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki, Greece
Interests: gynecologic oncology; advance laparoscopic surgery; robotic surgery; clinical research

Special Issue Information

Dear Colleagues,

Gynecologic oncology advancement is characterized by the continuous and increasing enrollment of molecular markers in daily clinical practice, not only as predictive tools but also as basic determinants of therapeutic management. Endometrial cancer guidelines set the molecular classification of disease as a primary component of the therapeutic algorithm, while regarding ovarian cancer, modern therapeutic modalities are tailored to molecular targets that are identified on an individualized base, in an effort to optimize prognosis. Management of cervical and vulvar cancer are relatively characterized by the implementation of relative strategies. In this context, this Special Issue extends a call for manuscripts related to the implementation of molecular targets in the modern therapeutic management of gynecological cancer. Original research articles, comprehensive reviews, systematic reviews and meta-analyses are the types of manuscripts that adhere to this Special Issue’s scope. We aim to compile a collection of high-quality evidence about molecular markers and targets in modern gynecologic oncology.

Dr. Stamatios Petousis
Dr. Chrysoula Margioula-Siarkou
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • endometrial cancer
  • ovarian cancer
  • cervical cancer
  • vulvar cancer
  • biomarker
  • molecular classification
  • targeted therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 484 KB  
Article
Evaluation of Human and Viral Methylation, in Addition to Partial Genotyping, for a Molecular Triage Strategy in Women Under Active Surveillance for CIN2
by Silvia Gori, Helena Frayle, Alessio Pagan, Marika Soldà, Cesare Romagnolo, Egle Insacco, Licia Laurino, Mario Matteucci, Giuseppe Sordi, Enrico Busato, Manuel Zorzi, Tiziano Maggino and Annarosa Del Mistro
Cancers 2026, 18(13), 2067; https://doi.org/10.3390/cancers18132067 (registering DOI) - 25 Jun 2026
Abstract
Background/Objective: Cervical intraepithelial neoplasia grade 2 (CIN2) shows heterogeneous clinical behavior, with substantial rates of spontaneous regression under active surveillance. Reliable molecular biomarkers are needed to distinguish regressive from transforming lesions and reduce overtreatment. We evaluated the prognostic role of host and [...] Read more.
Background/Objective: Cervical intraepithelial neoplasia grade 2 (CIN2) shows heterogeneous clinical behavior, with substantial rates of spontaneous regression under active surveillance. Reliable molecular biomarkers are needed to distinguish regressive from transforming lesions and reduce overtreatment. We evaluated the prognostic role of host and viral DNA methylation, alone and combined with HPV genotyping, in predicting CIN2 regression. Methods: This subanalysis derives from a prospective, multicenter Italian cohort of women with histologically confirmed CIN2 managed conservatively. Among 319 enrolled women, 134 with single HPV infections and valid host (FAM19A4/miR124-2) and viral (HPV L1 region) methylation results were included. HPV genotyping was performed with partial stratification (HPV16/18 vs. non-16/18). Clinical outcomes at 24 months were classified as regression versus persistence/progression. Logistic regression models assessed associations between biomarkers and regression. Results: At 24 months, 50% of women showed regression. Host and viral methylation positivity rates were more frequent in non-regressive lesions (40.3% vs. 19.4%, p = 0.01, and 52.2% vs. 32.8%, p = 0.02, respectively). Negative host methylation was significantly associated with regression (Odds Ratio OR = 0.37, 95% CI 0.17–0.81, p = 0.02), as was negative viral methylation (OR = 0.47, 95% CI 0.23–0.96, p = 0.04). Conclusions: Both host and viral methylation are inversely associated with CIN2 regression. Combining methylation markers did not substantially improve predictive accuracy; however, methylation negativity emerged as a potential molecular reassurance marker. When integrated with HPV genotyping, the highest probability of regression was observed among women with non-HPV16/18 infections and negative methylation results. These results endorse DNA methylation testing as a molecular tool for the conservative management of CIN2. Full article
(This article belongs to the Special Issue Molecular Markers and Targets in Modern Gynecologic Oncology)
Show Figures

Figure 1

Back to TopTop